FY2024 Earnings Estimate for MIRA Issued By Zacks Small Cap

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) – Investment analysts at Zacks Small Cap decreased their FY2024 earnings per share estimates for shares of MIRA Pharmaceuticals in a research note issued to investors on Tuesday, March 4th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings of ($0.66) per share for the year, down from their previous estimate of ($0.60). The consensus estimate for MIRA Pharmaceuticals’ current full-year earnings is ($0.60) per share.

MIRA Pharmaceuticals Price Performance

NASDAQ MIRA opened at $1.01 on Thursday. The stock’s 50 day simple moving average is $1.16 and its 200-day simple moving average is $1.31. The company has a market cap of $16.73 million, a PE ratio of -1.80 and a beta of 2.31. MIRA Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $5.01.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new stake in shares of MIRA Pharmaceuticals during the fourth quarter worth $28,000. Citadel Advisors LLC acquired a new position in MIRA Pharmaceuticals during the fourth quarter worth about $112,000. Northern Trust Corp grew its stake in MIRA Pharmaceuticals by 50.9% during the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock valued at $35,000 after acquiring an additional 10,238 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in MIRA Pharmaceuticals in the 4th quarter valued at about $52,000. Finally, Virtu Financial LLC purchased a new position in MIRA Pharmaceuticals in the 4th quarter worth approximately $72,000. Hedge funds and other institutional investors own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.